Printer Friendly Version View printer-friendly version
<< Back
Natera Announces Third Quarter 2019 Earnings Conference Call

SAN CARLOS, Calif., Oct. 30, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2019, after the market close on November 6, 2019. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities, and financial outlook.

Natera, Inc. Logo (PRNewsFoto/Natera, Inc.)

Earnings Conference Call Information:

Event: 

Natera's Third Quarter 2019 Financial Results Conference Call

Date: 

Wednesday, November 6, 2019

Time: 

1:30 p.m. PT (4:30 p.m. ET)

Live Dial-In: 

(877) 823-0171, Domestic


(617) 500-6932, International

Conference ID: 

4354617

Webcast: 

https://edge.media-server.com/mmc/p/vv47vu54

A webcast replay will be available at investor.natera.com.

About Natera
Natera is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on reproductive health, oncology, and organ transplantation. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com. Follow Natera on LinkedIn.

Contacts
Investor Relations
Mike Brophy, CFO, Natera, 650-249-9090
Media
Allison Rogan, pr@natera.com 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/natera-announces-third-quarter-2019-earnings-conference-call-300947841.html

SOURCE Natera, Inc.

Footer disclaimer

Footer disclaimer

© Natera 2019. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.